Founded in 2006, 23andMe set out with an ambitious goal: To one day make the human genome searchable by becoming the go-to resource for personal genetic information. Leveraging DNA analysis technology and web-based interactive tools, the company developed a "Personal Genome Service" that allows anyone and everyone to access and better understand their genetic data, including their ancestry and predisposition to certain diseases. But, today, the company believes that its true differentiation and value proposition today derives from its crowdsourced research model, which lets users contribute their genetic data to studies and research with the goal of finding cures. So, when 23andMe was recently awarded its first patent for determining a user's risk for Parkinson's Disease, it was seen as a big validation of its novel research model. Naturally, 23andMe is eager to double down, so what better way to follow your first patent than with your first acquisition?Source: http://feedproxy.google.com/~r/Techcrunch/~3/ItRGjrD60BI/
No comments:
Post a Comment